Biotech Diligence & Strategic Intelligence
Expert analysis for high-stakes biotech decisions
Solidus Bio helps early-stage biotech companies and investors evaluate assets, map competitive and patent landscapes, and sharpen strategy with analyst-grade research powered by proprietary data tools.
Who We Work With
Strategic Support for Key Decision-Makers
Biotech Founders & Executives
Sharpen your pipeline strategy, evaluate competitive positioning, and build the diligence materials investors and partners expect.
Business Development Teams
Get the competitive landscape, patent, and market data you need to evaluate targets and support deal conversations.
Investors & Diligence Teams
Assess scientific differentiation, IP risk, and market opportunity before capital is committed or a deal progresses.
Services
Built Around the Decisions That Matter Most
Solidus Bio supports biotech companies and investors with focused analysis across diligence, competitive landscapes, intellectual property, and market strategy.
Investment & Partnering Diligence
You need to evaluate a target, asset, or competitive context before committing capital or advancing a partnership.
For: Investors, BD teams, biotech executives · Engagement: Defined project
IP & Competitive Landscape Strategy
You need to understand who owns what, where the white space is, and how your IP position compares.
For: Biotech founders, patent counsel, R&D leadership · Engagement: Defined project or retainer
Market & Indication Prioritization
You need to decide where to focus — which indications, markets, or development strategies offer the best risk-adjusted opportunity.
For: Biotech executives, commercial strategy teams, investors · Engagement: Defined project
Ongoing Biotech Intelligence
You need to stay current on competitive activity, deals, patents, and scientific developments without building an internal team.
For: Biotech leadership, BD teams, investors with portfolio companies · Engagement: Recurring retainer
Technology-Enabled Consulting
Proprietary Tools That Power Deeper Analysis
Solidus Bio combines expert analysis with purpose-built data tools for faster diligence, deeper landscape analysis, and more scalable monitoring. Our platform integrates public data sources with AI to deliver insights that would take traditional approaches significantly longer.
- Clinical trial, drug, and sponsor intelligence database
- AI-orchestrated target discovery and prioritization
- Patent and competitive landscape monitoring
- Interactive dashboards and custom reports
Multi-Source Data
ClinicalTrials.gov, FDA, USPTO, OpenTargets, and more
AI-Powered Analysis
Natural language queries and automated scoring
Interactive Deliverables
Dashboards, reports, and visualizations
Selected Work
Example Engagements
Representative examples of how Solidus Bio can help clients make better-informed decisions.
Context
Series A biotech evaluating competitive risk before selecting lead indication
What We Can Deliver
- Target and asset landscape
- Patent activity summary
- Indication competitive map
- Strategic recommendation memo
Outcome
Refined prioritization and identified key diligence gaps before committing resources
Context
Investor conducting diligence on a platform technology acquisition
What We Can Deliver
- Scientific / technical diligence brief
- IP portfolio evaluation
- Competitor benchmarking analysis
- Red-flag and open-question list
Outcome
Surfaced critical IP risks and informed deal terms prior to term sheet
Context
Biotech BD team assessing partnership opportunities across multiple targets
What We Can Deliver
- Multi-target competitive landscape
- Deal activity and licensing trend analysis
- Market opportunity assessment
- Partner prioritization framework
Outcome
Narrowed partner shortlist and built a data-backed case for leadership review
About
Steven Ouellette, Ph.D.
Steve is the Founder of Solidus Bio and a USPTO-registered Patent Agent with deep expertise in molecular pharmacology. His career spans R&D, intellectual property, business development, and strategy across the biotech ecosystem.
Prior to founding Solidus Bio, Steve held roles at BostonGene, Ansa Biotechnologies, Cooley LLP, and co-founded KinaSense, where he developed a unique perspective at the intersection of science, IP, and commercial strategy.
Why This Perspective Matters
Solidus Bio sits at the intersection of biology, intellectual property, and commercial strategy. This combination means clients get analysis that connects scientific substance to business context — not just data, but decision-ready insight from someone who has worked across research, IP prosecution, and corporate development.
FAQ
Common Questions
Get Started
Discuss a Target, Asset, or Market Question
Tell us about the decision you're working on. Most engagements begin with a brief scoping call to align on the question, timeline, and deliverable format.